Bristol-Myers Squibb Company (BMY)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $128.63B
Last updated: Nov 17, 2026 at 4:37 PM ET
Bristol-Myers Squibb Company (BMY) Statistics
Bristol-Myers Squibb Company (BMY) has a market cap of $128.63B and an enterprise value of $161.94B. Its dividend yield is 4.00%.
Total Valuation
Enterprise value is 25.89% above the market cap, as debt exceeds cash.
| Market Cap | $128.63B |
|---|---|
| Enterprise Value | $161.94B |
| Latest price (Nov 17, 2026) | $62.93 |
Key Dates
The next earnings report is expected on Feb 3, 2027, covering the quarter ending Dec 31, 2026. The last ex-dividend date was Oct 2, 2026.
| Next Earnings Date | Feb 3, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 29, 2026 |
| Last Ex-Dividend Date | Oct 2, 2026 |
| Last Payment Date | Nov 2, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 2.6x and 5.5x. Its year-end P/E ranged from 6.9x to 49.6x from 2016 to 2025.
| P/E Ratio | 10.1x |
|---|---|
| Forward P/E | 9.6x |
| P/S Ratio | 2.6x |
| Forward P/S | 2.6x |
| P/B Ratio | 5.5x |
| P/FCF Ratio | 13.9x |
| P/OCF Ratio | 12.1x |
Enterprise Valuation
Counting debt and cash, the company is valued at 11.5x EBITDA and 17.4x free cash flow.
| EV / Earnings | 17.5x |
|---|---|
| EV / Sales | 3.2x |
| EV / EBITDA | 11.5x |
| EV / EBIT | 14.3x |
| EV / FCF | 17.4x |
Price Statistics
The stock is up 32.31% over 52 weeks and trades 2.18% above its 50-day average.
| Beta (1Y) | 0.23 |
|---|---|
| 52-Week Change | +32.31% |
| 1-Month Change | +5.32% |
| 3-Month Change | -3.74% |
| 6-Month Change | +12.14% |
| 5-Year Change | +6.99% |
| 10-Year Change | +22.73% |
| Total Return (1Y) | +37.61% |
| Total Return (3Y CAGR) | +10.94% |
| Total Return (5Y CAGR) | +4.66% |
| Return vs SPY (1Y) | +25.17% |
| Max Drawdown (1Y) | -15.91% |
| Max Drawdown (3Y) | -30.71% |
| Sharpe Ratio (1Y) | 1.15 |
| Correlation with SPY (1Y) | 0.12 |
| 50-Day Average | $61.59 |
| 200-Day Average | $59.63 |
| 52-Week Range | $43.34 to $67.94 |
| RSI (14 Days) | 53.8 |
| Average Volume (20 Days) | 10.04M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.59x current liabilities, and total debt is 1.83x shareholder equity.
| Current Ratio | 1.59x |
|---|---|
| Quick Ratio | 1.44x |
| Debt / Equity | 1.83x |
| Debt / EBITDA | 3.04x |
| Debt / FCF | 4.62x |
Returns and Efficiency
Return on invested capital is 13.95% over the last 12 months, against a 5-year average of 5.55%.
| Return on Equity (ROE) | 39.48% |
|---|---|
| Return on Assets (ROA) | 10.41% |
| Return on Invested Capital (ROIC) | 13.95% |
| Return on Capital Employed (ROCE) | 16.19% |
| ROE (5Y Average) | 10.15% |
| ROA (5Y Average) | 3.92% |
| ROIC (5Y Average) | 5.55% |
| Asset Turnover | 0.54x |
| Inventory Turnover | 6.78x |
| Receivables Turnover | 4.72x |
| Cash Conversion Cycle | 44 days |
Taxes
Income tax took 18.43% of pretax income over the last 12 months.
| Income Tax (TTM) | $2.09B |
|---|---|
| Effective Tax Rate | 18.43% |
Scores
BMY has an Altman Z-Score of 2.65, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 8 of 9, in the strong band of 8 or 9.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 2.65 |
|---|---|
| Altman Z Zone | Grey |
| Piotroski F-Score | 8 of 9 |
| Piotroski Strength | Strong |
Income Statement
Revenue of $50.03B over the last 12 months is up 4.16% from the 12 months before.
| Revenue | $50.03B |
|---|---|
| Revenue Growth (YoY) | +4.16% |
| Gross Profit | $31.60B |
| Operating Income | $11.56B |
| Pretax Income | $11.33B |
| Net Income | $9.24B |
| EBITDA | $14.12B |
| EBIT | $11.33B |
| Reported EPS (TTM) | $6.23 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 26.36% of the $88.77B in total assets.
| Cash and Equivalents | $9.57B |
|---|---|
| Total Debt | $42.88B |
| Net Debt | $33.30B |
| Net Debt Per Share | $16.29 |
| Working Capital | $11.01B |
| Shareholder Equity | $23.40B |
| Book Value Per Share | $11.45 |
| Tangible Book Value | -$15.27B |
| Total Assets | $88.77B |
| Total Liabilities | $65.37B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.37B of capital spending, operating cash flow left $9.29B of free cash flow.
| Operating Cash Flow | $10.65B |
|---|---|
| Capital Expenditures | $1.37B |
| Free Cash Flow | $9.29B |
| FCF Per Share | $4.55 |
| Depreciation and Amortization | $2.79B |
| Dividends Paid | $5.12B |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 23.10%, against a 5-year average of 11.06%.
| Gross Margin | 63.16% |
|---|---|
| Operating Margin | 23.10% |
| Pretax Margin | 22.65% |
| Net Margin | 18.47% |
| EBITDA Margin | 28.23% |
| EBIT Margin | 22.65% |
| FCF Margin | 18.56% |
| Gross Margin (5Y Average) | 66.66% |
| Operating Margin (5Y Average) | 11.06% |
| Net Margin (5Y Average) | 8.58% |
Growth
Revenue grew 1.45% a year over 3 years, and EPS fell 7.22% a year.
| Revenue Growth (3Y CAGR) | +1.45% |
|---|---|
| Revenue Growth (5Y CAGR) | +2.54% |
| EPS Growth (3Y CAGR) | -7.22% |
| EPS Growth (5Y CAGR) | -0.92% |
| FCF Growth (3Y CAGR) | +2.44% |
| FCF Growth (5Y CAGR) | -0.69% |
| Operating Income Growth (3Y CAGR) | +6.46% |
Dividends and Yields
BMY pays out 48.36% of earnings as dividends.
| Dividend Per Share (Annual) | $2.52 |
|---|---|
| Dividend Yield | 4.00% |
| Payment Schedule | Quarterly |
| Dividend Growth (3Y CAGR) | +4.71% |
| Dividend Growth (5Y CAGR) | +1.61% |
| Payout Ratio | 48.36% |
| FCF Payout Ratio | 55.13% |
| Earnings Yield | 9.90% |
| FCF Yield | 7.22% |
| Shareholder Yield | 3.98% |
Stock Splits
The last split was a 2-for-1 forward split on Mar 1, 1999.
| Last Split Date | Mar 1, 1999 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 2:1 |
Peer Position
Against 9 similar companies, BMY has the 9th highest P/E.
P/E RatioPeer median 21.3x
P/S RatioPeer median 4.9x
ROICPeer median 13.48%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +6.13%
Dividend YieldPeer median 2.37%
| P/E Ratio | 10.1x vs 21.3x median |
|---|---|
| P/S Ratio | 2.6x vs 4.9x median |
| ROIC | 13.95% vs 13.48% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +4.16% vs +6.13% median |
| Dividend Yield | 4.00% vs 2.37% median |
Analyst Forecast
Consensus estimates put revenue growth at 0.63% and EPS growth at 4.37% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +0.63% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +4.37% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About BMY
What is BMY's market cap?
Bristol-Myers Squibb Company has a market cap of $128.63B. Its enterprise value, which adds debt and subtracts cash, is $161.94B.
What is BMY's P/E ratio?
Bristol-Myers Squibb Company has a trailing P/E ratio of 10.1x and a forward P/E of 9.6x.
How many shares of BMY are outstanding?
Bristol-Myers Squibb Company has 2.04B shares outstanding. The count is up 0.41% from a year earlier.
Does BMY pay a dividend?
Yes. Bristol-Myers Squibb Company pays $2.52 a share a year, a dividend yield of 4.00%.
How much debt does BMY have?
Bristol-Myers Squibb Company has $42.88B of total debt and $9.57B of cash and equivalents, a net debt position of $33.30B.
BMY pages: Overview, Dividends, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts